Prevalence of HIV drug resistance before and 1 year after treatment initiation in 4 sites in the Malawi antiretroviral treatment program

Clinical Infectious Diseases

Volumn 54, Issue SUPPL. 4, 2012, Pages

  Wadonda Kabondo, Nellie ^a   Bennett, Diane ^b   Van Oosterhout, Joep J ^c   Moyo, Kundai ^a   Hosseinipour, Mina ^d   Devos, Josh ^b   Zhou, Zhiyong ^b   Aberle Grasse, John ^b   Warne, Thomas R ^e   Mtika, Clement ^a   Chilima, Ben ^a   Banda, Richard ^f   Pasulani, Olesi ^g   Porter, Carol ^h   Phiri, Sam ⁱ   Jahn, Andreas ^a   Kamwendo, Debbie ^d   Jordan, Michael R ^f,j   Kabuluzi, Storn ^a   Chimbwandira, Frank ⁱ   Kagoli, Mathew ^a   Matatiyo, Blackson ^k   Demby, Austin ^e   Yang, Chunfu ^b   more..

^a MINISTRY OF HEALTH   (Malawi)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c UNIVERSITY OF MALAWI   (Malawi)

^d UNIVERSITY OF NORTH CAROLINA PROJECT   (Malawi)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^f WORLD HEALTH ORGANIZATION   (Switzerland)

^g World Health Organization ^*  (Belgium)

^h 10Howard University Technical Assistance Project   (Malawi)

ⁱ LIGHTHOUSE TRUST   (Malawi)

^j TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k National AIDS Commission   (Malawi)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; CLINICAL CLASSIFICATION; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEALTH PROGRAM; HIV EDUCATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; MALAWI; MALE; NONHUMAN; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; VIRUS LOAD; VIRUS RESISTANCE; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALAWI; MALE; MEDICATION ADHERENCE; NATIONAL HEALTH PROGRAMS; PREVALENCE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84860369254     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir987     Document Type: Review

References (28)

1. The Republic of Malawi Ministry of Health. HIV and syphilis serosurvey and national HIV prevention and AIDS estimates report for 2007. 2007. Available at: http://www.huvunitmohmw.org/Main/HIVMeetingsAndHIVUnitReports. Accessed 13 April 2011.
2. Mee P, Fielding KL, Charalambous S, Churchyard GJ, Grant AD. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS 2008; 22:1971-7.
3. Moore DM, Mermin J, Awor A, Yip B, Hogg RS, Montaner JS. Performance of immunologic responses in predicting viral load suppression: implications for monitoring patients in resource-limited settings. J Acquir Immune Defic Syndr 2006; 43:436-9. (Pubitemid 44737101)
4. Reynolds SJ, Nakigozi G, Newell K, et al. Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS 2009; 23:697-700.
5. Hosseinipour MC, van Oosterhout JJG, Weigel R, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009; 23:1127-34.
6. Jordan MR, Bennett DE, Bertagnolio S, Gilks CF, Sutherland D. World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir Ther 2008; 13(Suppl 2):15-23. (Pubitemid 352019086)
7. Koyalta D, Charpentier C, Beassamda J, et al. High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad. Clin Infect Dis 2009; 49:155-9.
8. Marcelin A-G, Jarrousse B, Derache A, et al. HIV drug resistance after the use of generic fixed-dose combination stavudine/lamivudine/nevirapine as standard first-line regimen. AIDS 2007; 21:2341-3. (Pubitemid 350287461)
9. Maldonado F, Biot M, Roman F, et al. Viraemia and HIV-1 drug resistance mutations among patients receiving antiretroviral treatment in Mozambique. Trans R Soc Trop Med Hyg 2009; 103:607-12.
10. Barth RE, Tempelman HA, Smelt E, Wensing AM, Hoepelman AI, Geelen SP. Long-term outcome of children receiving antiretroviral treatment in rural South Africa: substantial virologic failure on first-line treatment. Pediatr Infect Dis J 2011; 30:52-6.
11. KamyaMR, Mayanja-KizzaH, Kambugu A, et al. Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr 2007; 46:187-93. (Pubitemid 47482614)
12. Kouanfack C, Montavon C, Laurent C, et al. Low levels of antiretroviral-resistant HIV infection in a routine clinic in Cameroon that uses the World Health Organization (WHO) public health approach to monitor antiretroviral treatment and adequacy with the WHO recommendation for second-line treatment. Clin Infect Dis 2009; 48:1318-22.
13. Wallis CL, Mellors JW, Venter WD, Sanne I, Stevens W. Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 2009; 53:480-4.
14. Marconi VC, Sunpath H, Lu Z, et al. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis 2008; 46:1589-97. (Pubitemid 351706742)
15. Puthanakit T, Jourdain G, Hongsiriwon S, et al. HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. HIV Med 2010; 11:565-72.
16. Sungkanuparph S, ManosuthiW, Kiertiburanakul S, Saekang N, Pairoj W, Chantratita W. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine. J Clin Virol 2008; 41:310-3.
17. Oyugi JH, Byakika-Tusiime J, Ragland K, et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS 2007; 21:965-71. (Pubitemid 46684328)
18. Wadonda-Kabondo NH, Hedt BL, van Oosterhout JJ, et al. A retrospective survey of HIV drug resistance among patients one year after initiation of antiretroviral therapy at four clinics in Malawi. Clin Infect Dis 2012; 54(Suppl 4):S356-61.
19. Yang C, McNulty A, Diallo K, et al. Development and application of a broadly sensitive dried-blood-spot-based genotyping assay for global surveillance of HIV-1 drug resistance. J Clin Microbiol 2010; 48:3158-64.
20. Hall T. A user-friendly biological sequence alignment editor and analysis program for window96/98/NT. Nucleic Aids Symp Ser 1999; 41:95-8.
21. Tamura K, Dudley J, Nei M, Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4. 0. Mol Biol Evol 2007; 24:1596-9. (Pubitemid 47236692)
22. Alamos L. Los Alamos HIV database 2011. 2011; Available at: http://www.hiv. lanl.gov/content/sequence/NEWALIGN/align.html. Accessed 4 April 2011.
23. Rhee S, Gonzales MJ, Kantor R, et al. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Research 2003; 31:298-303. (Pubitemid 36150389)
24. Tweya H, Gareta D, Chagwera F, et al. Early active follow-up of patients on antiretroviral therapy (ART) who are lost to follow-up: the "Back-to-Care" project in Lilongwe, Malawi. Trop Med Int Health 2010; 15(Suppl 1):82-9.
25. Toure S, Kouadio B, Seyler C, et al. Rapid scaling-up of antiretroviral therapy in 10, 000 adults in Cote d'Ivoire: 2-year outcomes and determinants. AIDS 2008; 22:873-82. (Pubitemid 351563837)
26. Bocket L, Yazdanpanah Y, Ajana F, et al. Thymidine analogue mutations in antiretroviral-naive HIV-1 patients on triple therapy including either zidovudine or stavudine. J Antimicrob Chemother 2004; 53: 89-94. (Pubitemid 38072188)
27. Reisner SL, Mimiaga MJ, Skeer M, Perkovich B, Johnson CV, Safren SA. A review of HIV antiretroviral adherence and intervention studies among HIV-infected youth. Top HIV Med 2009; 17:14-25.
28. Chilton D, Dervisevic S, Pillay D, et al. Determinants of HIV drug resistance mutations in plasma virus after treatment interruption. AIDS 2005; 19:2174-5. (Pubitemid 41669010)